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Abstract
Background: The global interest in developing therapies for Ebola infection management and its prevention is
laudable. However the plan to conduct an emergency immunization program specifically for healthcare workers
using experimental vaccines raises some ethical concerns. This paper shares perspectives on these concerns and
suggests how some of them may best be addressed.
Discussion: The recruitment of healthcare workers for Ebola vaccine research has challenges. It could result in
coercion of initially dissenting healthcare workers to assist in the management of EVD infected persons due to
mistaken beliefs that the vaccine offers protection. It could also affect equity and justice. For example, where people
who are not skilled health care professionals but who provide care to patients infected with Ebola (such as in home care
settings) are not prioritized for vaccination. The possibility of study participants contracting Ebola infection despite the
use of experimental vaccine, and the standard of care they would receive, needs to be addressed clearly, transparently
and formalized as part of the ethics review process. Future access to study products in view of current status of the
TRIPS agreement needs to be addressed. Finally, broad stakeholder engagement at local, regional and international
levels needs to be promoted using available communication channels to engage local, regional and international
support. These same concerns are applicable for current and future epidemics.
Summary: Successful Ebola vaccine development research requires concerted efforts at public dialogue to address
misconceptions, equity and justice in participant selection, and honest discussions about risks, benefits and future access.
Public dialogue about Ebola vaccine research plans is crucial and should be conducted by trusted locals and negotiated
between communities, researchers and ethics committees in research study sites.
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Background
The recent outbreak of Ebola Virus Disease (EVD),
which is still ongoing in Guinea and Sierra Leone, is the
worst in history. The spread of the EVD from Africa to
Europe and North America has heighted international
concerns about EVD including the prospect for the virus
being used for bioterrorism [1]. The recognition of the-
catastrophic potential of EVD has also brought a sense
of urgency to the development of therapeutic and pre-
ventative interventions. Many governments and donors
are not only devoting financial and human resources to
support the response to the current outbreak in West
Africa, they are also supporting research for improved
control of EVD [2].
At present, there is no approved specific therapy or
vaccine for EVD. Supportive clinical care, which includes
aggressive fluid and electrolyte replacement, and anti-
biotic therapy have been the most promising care for
EVD patients in the affected West African countries [3].
The use of antiemetics and antidiarrheal medications is
also important to reduce massive gastrointestinal losses
and the consequences of hypovolemic shock [4–7]. Pro-
viding optimal intensive care services, including options
like dialysis that are available in resource-rich countries
[8, 9], are likely to save more lives, but are widely un-
available in affected resource-poor countries.
While new therapeutic approaches and new preventive
interventions are often discussed together, it is import-
ant to distinguish between them when considering both
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the potential benefits and the ethical challenges involved
in their research and development processes. The devel-
opment of treatments that directly target the Ebola virus
offer the greatest promise of reducing the case fatality
associated with EVD, while the development of pre-
ventative vaccines would be valuable in reducing trans-
mission and limiting the size of future epidemics.
Also, multiple reports allude to the weakened health
systems in the region as a significant factor in the spread
of EVD [10, 11]. Additionally, there are historical and cul-
tural factors that limited the early control of the outbreak.
The history of government mistrust [12], denial of the ex-
istence of EVD [13, 14] and the prevalent myths and mis-
conceptions about EVD including conspiracy theories
about Northern exploitation of the South. The latter in-
clude the real histories of the slave trade, European coloni-
alism, unfavorable economic and trade policies, and
resource conflicts, all of which involved Northern inter-
ventions in alliance with government and other national
elites [15]. Conducting EVD vaccine research poses ethical
challenges in a region that possesses low confidence in the
goodwill of government and foreigners – a challenge that
is all the more difficult given low scientific literacy as well
as a limited time frame in which to conclude research be-
fore the epidemic ends.
One of the key issues under discussion with regard to
testing EVD vaccines is finding the appropriate popula-
tion group to participate in the research. Healthcare
workers who are involved with case management are at
high risk of contracting EVD because of their close
contact with patients during the most infectious period:
when patients are highly symptomatic [15]. They are
therefore prioritized as study participants for EVD
vaccine research [16].
This article specifically addresses concerns and con-
texts pertaining to EVD vaccine development. We
present ethical arguments against plans to exclusively
target professional healthcare workers for experimen-
tal EVD vaccineII/III clinical studies [17]. We suggest
there are fairer ways to prioritize people at high risk
of infection – which includes, but is not limited to
professional healthcare workers – than giving only
one group of people privileged access to experimental
products based on occupational status. We will
further discuss the ethical challenges pertaining to the
design and implementation of EVD vaccine research.
These concerns include the appropriateness of
randomization of study participants to control arms
and the adequacy of care for vaccine trial partici-
pants [18], issues that are subject to ongoing debate
[19–25]. We will also argue for the critical need to
create and sustain community engagement processes
and to promote community-level understanding of
EVD vaccines; these are especially important
considering the real concerns about the level and
nature of community engagement efforts in the field
[26]. The issues of access to proven effective EVD
vaccines by poor governments and or communities
will also be addressed. Finally, we discuss the need
to build human capacity for health research and pro-
gramming purposes because prospects for future
emerging diseases require prompt regional responses.
Debate
Current EVD vaccine candidates and associated ethical
dilemmas
The preliminary result of the phase III Ebola ça Suffit
trial, which tested the vaccine candidate rVSV-ZEBOV
were released on 31 July 2015. The result showed prom-
ising evidence of high vaccine efficacy: no participants
who received immediate vaccination developed EVD
10 days or more after the contact (10–21 days is the in-
cubation period and so, developing EVD prior to 10 days
indicates that the person may have had exposure prior
to the vaccination) [27]. The trial used an adaptive de-
sign modelled on the ‘ring’ vaccine strategy, previously
used to eradicate smallpox in the 1970s (though in the
case of smallpox, a known effective vaccine was used)
[28]. ‘Ring’ methodology uses a contact tracing approach
to first identify people known to have been in contact
with a diagnosed index case, and then to offer them vac-
cination. In order to have an experimental aspect in the
Ebola ça Suffit trial, communities participating in the
trial were treated as ‘clusters’, and randomized either to
immediate vaccination of contacts upon identification of
an index case, or delayed vaccination, with contacts vac-
cinated 21 days after contact with the index case.
A key feature of the Ebola ça Suffit design is that it
did not have a placebo arm. Also, it prioritized access to
the vaccine candidate for all people at highest risk (i.e.,
those who had had contact with a diagnosed index case).
The randomization to immediate vaccination compared
with delayed vaccination, using carefully calibrated tim-
ing, meets the principle of distributive justice while still
allowing experimental comparison between groups.
The rVSV-ZEBOV vaccine candidate is also being tested
in two other trials: a phase II study in Guinea that ran in par-
allel with the ‘ring’ study and targeted 1200 ‘frontline’
workers (healthcare workers and other personnel such as
members of laboratory, ambulance, burial or surveillance
teams) [29]; and a phase III study in Sierra Leone called the
STRIVE trial [30]. A third study called the PREVAILstudy
[31], was to test rVSV-ZEBOV against another candidate,
ChAd3-EBO Z, and placebo, in a general population group.
This third trial was to take place in Liberia and targets
‘healthy adults’ in the region – a category that includes but is
not limited to those at highest risk. The study is likely to be
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moved to Guinea due to the containment of the infection in
Liberia [32].
Like Ebola ça Suffit, the STRIVE trial was designed
to avoid the use of placebo: it used an immediate and
deferred vaccination strategy: ‘immediate’ vaccination
was at enrollment, while ‘deferred’ was about six
months after enrollment (significantly later than the
‘ring’ trial). Randomization was at individual rather
than cluster level, and vaccine efficacy was assessed
by the different rates of EVD infection observed
between those vaccinated and those not yet vacci-
nated [30]. The merit of this study design from an
ethical perspective is the avoidance of the use of a
placebo in a study population at very high risk for an
often fatal infection. However, the study was not
blinded thereby introducing some bias: those who
receive delayed vaccination may practice personal
protection better than those who receive immediate
vaccination. The length of the delay for those in the
deferred group is an ethical concern: the incubation
period of EVD is 21 days, and waiting 6 months for
vaccination during an epidemic greatly increases the
likelihood of exposure and infection. Also, the undue
delay prolongs the study period during an epidemic
that is known to decline over time even with limited
intervention.
The design of the PREVAIL study also raises ethical
issues: it has a placebo arm. While there was no evi-
dence that either of the candidate vaccines offered
any benefit over a placebo at the time of study de-
sign, there has been considerable discussion that the
dire circumstances of the Ebola outbreak necessitated
a different approach to studying the efficacy of candi-
date vaccines: access to experimental interventions
should have higher priority over the use of a random-
ized clinical trial design for EVD vaccine efficacy
studies [14, 16, 17].
We expect that with the evidence from the Ebola
çb Suffit study trial, there will be reconsiderations on
the delayed vaccination strategy and/or use of placebo
in the STRIVE and PREVAIL as well as other EVD
vaccine trials. It is our opinion that with the results
from the Ebola çb Suffit study, it is difficult to satisfy
the clinical equipoise principle. A placebo arm is eth-
ically justified when there is genuine uncertainty in
the scientific community as to which of several op-
tions is better [33]. It would thus be unethical to
randomize people to delayed vaccination and/or pla-
cebo arms considering the high risk of infection and
case fatality rates related to EVD. Likely savings from
changes in the designs would ensure that maximum
resources are committed to the candidate most likely
to result in an effective implementation EVD preven-
tion programs, including consideration of whether
there are surrogate immunological markers of vaccine
efficacy that could be used to assess subsequent
vaccines.
Ethical concerns with prioritizing healthcare providers for
EVD vaccine research
One of the key ethical advantages of the ‘ring’ vaccination
approach is that access to vaccination is directly related to
risk – known exposure to an index case. We contend that
in the circumstances of the West African Ebola outbreak,
using known risk as a determinant for access is preferable
to using occupational status. While experimental EVD
vaccine research is associated with unknown risk,
prioritization of healthcare workers as study participants
for EVD vaccine research would also concentrate the ben-
efits of research participation in a small population pool.
Several authors have made the converse argument with
respect to experimental interventions - that in the foresee-
able event that access to experimental interventions must
be rationed, healthcare workers should be prioritized over
other candidates [34, 35].
Elsewhere, we have argued against prioritizing access
to experimental treatment interventions for frontline
workers on the basis that it could exacerbate existing in-
equalities [36–39] and that all people with a life threat-
ening illness have the same moral right to treatment.
We however consider that there is stronger moral justifi-
cation for prioritizing healthcare providers – professional
healthcare workers, laboratory personnel, ambulance
staff, and burial or surveillance team members - as study
participants for experimental EVD candidate vaccines
for the following reasons. First, healthcare providers are
among those at highest risk for EVD infection. Second,
while an experimental vaccine might not confer any pro-
tective benefit, healthcare providers may be better placed
to understand the potential risks and benefits of un-
proven agents, given that many might possess better
knowledge of clinical and research concepts that are key
to getting informed consent to experimental interven-
tions. These include understanding the concept of
randomization and the fact that EVD vaccine trials does
not connote proven efficacy of candidate vaccine. For
those personnel who may lack access to medical or clin-
ical education such as those involved in public health
tasks like burial, being in a workplace where discussion
about these concepts can occur is likely to enhance un-
derstanding of EVD vaccine trials, and it can reduce the
chances of a vaccine trial being misunderstood as an
Ebola therapy (i.e., therapeutic misconception). The
plausibility of professional healthcare providers not
being familiar with clinical trials concepts is real: many
years of wars and conflicts in the region have resulted in
little investment in clinical trials in the region when
compared with Southern and Eastern Africa. EVD
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vaccine researchers need to be aware of this potential
challenge and develop contingency plans to improve
healthcare providers’ understanding of clinical trial de-
sign and implementation either as trialists or as study
participants.
Prioritizing healthcare providers as study participants
for EVD vaccine clinical trials comes with other chal-
lenges. Targeting healthcare providers as study partici-
pants for EVD vaccine research has the potential to
motivate governments of affected nations to compel health
care providers to participate in vaccine research so they
can provide care for patients infected with EVD. Compul-
sory recruitment of healthcare providers to participate in
EVD response programmes has occurred in the past [40]
and is a serious concern, as some health care providers
hesitate to provide care because of their heightened risk
for EVD [3, 41]. Yakubu et al. [39] argued that health care
providers in EVD affected region are under no profes-
sional obligation to provide care for patients infected with
EVD given that their safety in the occupational setting
cannot be assured, even when following protocols regard-
ing personal protective equipment (PPE).
Nevertheless we recognize that there are many profes-
sional healthcare providers who are willing to continue to
provide care despite the risks. Prioritized access to ex-
perimental EVD vaccines should not, however, be pro-
mulgated as a benefit given that efficacy of an
experimental intervention is uncertain. Members of the
general population who are willing to provide health care
services for patients with EVD infection, those who vol-
unteer to serve as home based care providers, those who
volunteer to provide treatment for patients with EVD at
treatment centers, and those involved in public health
practices such as contact tracing and public health educa-
tion, should also be included as potential study partici-
pants, because they too are at heightened risk for EVD
infection. As demonstrated by the ‘ring’ concept used in
the rVSV-EBO trial in Guinea, whereby contacts and
“geographic neighbors” [42] of an infected individual
were identified and vaccinated, prioritizing access of all
persons at risk for EVD infection reduces the risk of the
trial being perceived as providing help to some and not
to others [43]. Another strength of this model is that it
uses the traditional public health process of contact tra-
cing in an innovative way that is likely to strengthen
contact tracing systems in-country; and it is likely to pro-
mote community support for contract tracing by demon-
strating its potential benefit beyond identifying
individuals not just for case isolation only. This model,
we contend, is an excellent example of an approach that
promotes equitable access of all persons at risk for EVD,
and one that respects the principle of justice [44].
The altruism displayed by many healthcare workers
who continue to provide care and support for patients
with EVD should be a reason to strengthen health sys-
tems and safety nets in ways that reduces the risk for in-
fection. This requires that a country’s disease
surveillance systems be built or strengthened, more
healthcare professionals trained, and laboratory capacity
built and strengthened. Healthcare workers’ participation
in an experimental EVD vaccine research would not
(and should not) allay concerns about the effectiveness
of current PPE [45], their heightened risk of infection
[41] and poor access of infected healthcare workers to
optimum care [46]. Experimental vaccination should also
not be used to alleviate fear of infection. Therefore, due
considerations need to be given to the standard of care
provided for EVD vaccine trial participants [18].
Similar to Satalkar et al’s [34] observation, differential
access to EVD care between international and local
health care workers who become infected at work raises
serious concerns. Differential access to care of persons
infected with EVD during the current EVD outbreak has
resulted in public discussions on the ethical obligation
to respond to the health risk of local and international
healthcare providersresponding to a national crisis [47].
These concerns are heightened if healthcare workers are
engaged in research. Differential access to standard of
care packages should not be dependent on nationality.
Guaranteeing access to quality care for all study partici-
pants who contract EVD infection or when serious ad-
verse events occur is important and would promote
interest in EVD vaccine research [40]. Directly address-
ing access to medical care and management of adverse
reactions associated with intervention research has been
central in the demands community members make to
researchers [48].
Community engagement with EVD vaccine trial design
and implementation
The sense of urgency surrounding EVD vaccine research
and the need to conduct clinical trials before the current
EVD epidemic ends, may compromise efforts to imple-
ment community education programs about EVD re-
search. The benefits of community engagement extend
beyond EVD trials. Over the long-term communities can
become more literate in clinical science and be engaged
in future research that directly impacts them. Moreover,
lack of community education increases the risk of thera-
peutic misconception particularly in communities where
research literacy is low [49]. Therapeutic misconception
may lead to increased risky practices due to beliefs in
vaccine efficacy. These challenges should not preclude
the recruitment of non-health professionals for EVD
clinical trials. It rather highlights why due considerations
should be given to planning and implementing rigorous
community education programs as part of the EVD vac-
cine research agenda.
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It is important that communities located in research
sites are made aware of research plans and the objectives
for experimental vaccination. Community engagement is
an ethical imperative as it ensures the integrity of re-
search processes and the applicability of research out-
comes. If we accept that proposed research should be
relevant to the needs of the affected community, then
the research design and the plans for implementation
need to be deemed acceptable by the community hosting
the research [50]. Community engagement facilitates the
research process fitting into larger concerns regarding
epidemiological landscapes, which is critical to under-
standing the EVD outbreaks as well as and making plans
to prevent future outbreaks. A clinical trial that proceeds
without established knowledge of the cultural nuances
that affects perceptions about health, infection and vac-
cinations could potentially create negative unforeseen ef-
fects [43].
The community engagement process requires that
community members are consulted at the beginning of
the research project in an open, collaborative process
[51]. Benefits of community consultation include
strengthening local ownership of the research, effective
communication between stakeholders, and the promo-
tion of mutual understanding between trial communities
and researchers [52]. Community engagement strategies
include training of laypersons on ethics committees to
reviewand provide constructive feedback on EVD vac-
cine protocols that addresses cultural context for study
implementation, developing plans to engage and dia-
logue with formal and informal community structures
about the research implementation [51], and discussing
benefit-sharing mechanisms [34]. These processes re-
quire the use of multiple communication tools that can
facilitate broad and wide-ranging communication proce-
dureswithin the short time available to conduct this
research. Such community engagement programs would
help promote understanding about the differences between
compassionate use of experimental EVD therapies and
EVD vaccines research. It can also promote community
support for recruiting and retaining study participants.
Low community involvement in EVD vaccine research
design and implementation, coupled with poor coordin-
ation among stakeholders could cause community frus-
tration, disillusionment and anger with the research
process. This is because communities often want to en-
gage in the agenda setting of medical research. These in-
clude questioning either the scientific logic that governs
basic research, clinical experimentation, product devel-
opment, clinical trial and product approval and the
lengthy timescale required to complete it. These ap-
proaches are essential for promoting true community
partnership in EVD vaccine research. The urgency sur-
rounding EVD vaccine development must not preclude
effective community engagement in research design and
study implementations that are reconciled with the pre-
cariousness of the everyday life of study participants.
Health care providers are critical stakeholder to engage
with during EVD vaccine clinical trial design and imple-
mentation. They need to be engaged in discussions
about vaccine development as a matter of urgency,
particularly regarding proposed plans to prioritize their
access as study participants. Failure to actively engage
healthcare providers in the study design and implemen-
tation may result in the slow recruitment of study partic-
ipants due to myths, misconceptions, stigma and fear.
Addressing myths and misconceptions
Myths and misconceptions have been shown to affect
the uptake of public health programs that involve vac-
cination [53]. Major concerns about vaccinations have
had to do with the possible long-term consequences of
harmful side effects and possible death. Spurious associ-
ations of immunization with morbidity and mortality
[54, 55] and misconceptions that the vaccine itself may
transmit a pathogen or cause sterility [56–58] have also
caused concerns about vaccinations. Specific myths and
misconceptions about EVD include beliefs that the West
African governments invented the Ebola epidemic for
the purpose of garnering foreign aid [23]. Another myth
is that the disease was introduced to Africa by white for-
eigners for the purpose of conducting drug tests [59].
These myths were fueled largely by the mistrust of the
government [22] and foreigners [23] following long, sim-
ultaneous histories of violent war and International
Monetary Fund and World Bank led structural adjust-
ment reforms that contributed to mass household pov-
erty [60, 61] – both were linked to illegal resource
extraction by government and foreigners. Ironically,
current EVD vaccine research are designed and mainly
implemented by researchers from the North with collab-
orations that include government officials and donor
partners thereby setting the stage for fueling myths and
misconceptions about EVD vaccine research. Moreover,
in some cases, health care providers are believed to trans-
mit EVD and are widely stigmatized as a result [62, 63]. As
such, mistrust of the research process may predispose
health care workers to a new form of stigma. These myths
and misconceptions could also affect uptake of proven
vaccines.
It is therefore important to prevent and address myths
and misconceptions about clinical trials in low research
literacy communities through extensive and continued
dialogue between researchers and community members.
The objective is not only to promote community accept-
ance and support of proposed clinical trials but also to
promote community literacy on the part of the re-
searcher so as to ensure research designs are sensitive to
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and respects sociocultural norms and values. Overall,
community engagement efforts should seek to ensure that
the EVD vaccine trials are integrated with local measures
that address differences in people’s capacities, preferences,
cultural commitments, and socioeconomic and environ-
mental circumstances. Then, EVD vaccine research efforts
would be seen to be prioritizing and protecting the health
of the affected communities [36, 37].
Negotiations for post-trial access
At the outset, clear and binding commitments are
needed to ensure access to approved EVD vaccines as
communities that participate in research and the coun-
tries that are affected by the epidemic may not be able
to afford the final research products. The Hepatitis B
vaccine is an example of a preventive agent that has not
been affordable for a number of countries that were in-
volved in its development [64]. Unfortunately, discussion
about post-trial access to EVD vaccine is currently lim-
ited. Yet, post-trial access for communities that engage
in international research is widely recognized as an im-
portant means to minimize exploitation and promote
the social value of research [50]. Post-trial access to EVD
vaccine is endorsed by the Declaration of Helsinki guide-
line 14, and the guideline 33 requires that arrangements
for post-trial access be described in the research study
protocol [65, 66]. Planning for post-trial access is there-
fore an ethical imperative.
However, as Zvonareva et al. [50] rightly pointed out,
benefit sharing is complicated by the non-specificity
regarding who ensures that benefits are made available.
Folayan et al. [18] have proposed that the World Health
Organization, which is currently engaged with coordin-
ating the EVD response in the region, should be allo-
cated the responsibility of ensuring post-trial access to
EVD drugs and vaccines. The TRIPs Agreement of the
World Trade Organization highly limits vaccine avail-
ability to low-income countries [67]. Unfortunately, spe-
cific discussions about EVD vaccine access and the
impact of TRIPs have not been given priority attention
[68]. The Global Alliance for Vaccine and Immunization
(GAVI) had actively addressed some of the challenges
associated with vaccine access in developing countries in
the past and may likely work with pharmaceutical com-
panies to address potential challenges that low-income
countries may face [69]. While GAVI’s engagement with
EVD vaccine access may be laudable, this approach pro-
motes continued dependency of resource poor countries
on donor support. One possible option to explore is
differential pricings for EVD vaccines for countries that
were engaged in the development of EVD vaccines [70, 71].
This would help make EVD vaccines affordable at least to
these countries while in addition, price consideration is also
given for other populations. Given that differential pricing
may not entirely ensure easy access, another laudable op-
tion would be to, at the outset, engage effected West Afri-
can governments in negotiations so that they can set firm
prices that they affirm they can afford. Such legal discus-
sions would ensure governments are held accountable to
citizens in terms of their commitment to directly address-
ing future EVD outbreaks. This option further reduces
donor dependency.
Facilitating the translation of research outcomes to prompt
product access
We need to learn and apply lessons from the recent past
to EVD vaccine research and development. Poor engage-
ment of community members in the design and imple-
mentation of research has marred past research
programs [48], limited prompt translation of research
outcomes to policies and programmes and the pace of
community uptake and use of approved products. The
poor uptake of polio vaccine in Northern Nigeria is a
good example. Despite the known benefits associated
with polio vaccination, the polio eradication program in
Nigeria has been marred with challenges related to poor
community trust and ownership of the polio vaccine
program [72]. Patient access to any developed EVD vac-
cine is critical, and effective translation from clinical tri-
als to implementation should be part of the planning
process.
Conclusion
We have argued that recruitment of study participants
for experimental EVD vaccine research should not target
only professional healthcare workers as this would en-
trench a sense of further marginalization in communities
especially those where human right abuses are rampant.
However, if the global agenda prioritizes enrollment of
healthcare workers for experimental vaccines, it would
be expedient for research teams to proactively hold pub-
lic dialogues and discussions with community members
and healthcare workers about the justification for priori-
tizing healthcare workers as study participants to experi-
mental EVD vaccines, and how experimental EVD
vaccine research differs from compassionate use of
experimental therapies for EVD management.
We also advocate that it would be wise to consider the
inclusion of other groups at heightened risk of infection
alongside professional healthcare workers. We consider
the ring design as a scientifically valid and ethically justi-
fied for the implementation of an EVD vaccine clinical
trial during a major epidemic. The ring design ensures
that all people at high risk of contracting EVD are re-
cruited into the study equitably. The utilization of con-
tact tracing as an element of the ring design helps
facilitate the active engagement of communities with
research implementation.
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Public discussions about EVD vaccine trial design and
implementation must be facilitated by trusted commu-
nity members to engender trust, and members of com-
munities in EVD stricken areas must have some say over
how this prioritization is managed so that inequities are
not further entrenched. The care needs of those involved
in the vaccine trial who become EVD infected, as some
inevitably will, must also form part of the discussion.
Care must be of high standard, evidence based, and
equitable for all research participants. The feasibility of
future access to EVD vaccines in future outbreaks also
needs to be included in ongoing discussions.
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